This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Autism Patients Could Be Helped with Cannabis

NEW YORK (TheStreet) -- Analysts may be underestimating the potential of GW Pharmaceuticals (GWPH). Five analysts are covering the company, the most recent initiation coming from Morgan Stanley. The average price target is $86 and the stock currently trades at $71.

GW Pharmaceuticals is known for its flagship drug Sativex, which combines both the THC and the CBD extracts from the cannabis plant for medicinal purposes. Sativex is delivered as a mouth spray and has been approved for use in countries like Great Britain, Canada and Germany to name a few. It is considered to be the only mainstream pharmaceutical company to pursue cannabis testing and scientific trials. Solvay Pharmaceuticals produces Marinol, a THC only drug, which is approved by the FDA in the U.S. Solvay has done no studies since 2004.

The analysts are mostly excited about the use of GW's drug Epidiolex for pediatric epilepsy, specifically Dravet Syndrome and the patients that suffer from Lennox Gastaut syndrome. They are fairly small patient populations, roughly 5,000 Dravet patients in the U.S. and 15,000 LGS. However, there is little competition and the patients' needs are mostly unmet. So GW will own this market.

WATCH: More feature videos on TheStreet TV | More videos from Debra Borchardt

Must Read: Perfect World is Now Oversold (PWRD)

The bigger potential market for GW Pharmaceuticals could be autism. PiperJaffrey analyst Josh Schimmer has noted that subsets of these diseases share similar features with epilepsy. He writes, "It's possible that some children have subclinical seizure activity that result in developmental disorders, and there are also extremely exciting anecdotes of autism patients who thrive after CBD therapy." According to the Center for Disease Control and Prevention, 1.5% of the children in the U.S. are diagnosed with ASD as of 2014, a huge patient population.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
GWPH $85.16 0.76%
AAPL $118.03 -0.71%
FB $105.41 -0.31%
GOOG $748.15 -0.02%
TSLA $229.64 5.22%


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs